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Abstract
Rapid detection of carbapenem-resistant Acinetobacter baumannii strains is critical and will benefit patient care by
optimizing antibiotic therapies and preventing outbreaks. Herein we describe the development and successful application
of a mass spectrometry profile generated by matrix-assisted laser desorption ionization-time of flight (MALDI-TOF) that
utilized the imipenem antibiotic for the detection of carbapenem resistance in a large series of A. baumannii clinical isolates
from France and Algeria. A total of 106 A. baumannii strains including 63 well-characterized carbapenemase-producing and
43 non-carbapenemase-producing strains, as well as 43 control strains (7 carbapenem-resistant and 36 carbapenem-
sensitive strains) were studied. After an incubation of bacteria with imipenem for up to 4 h, the mixture was centrifuged and
the supernatant analyzed by MALDI-TOF MS. The presence and absence of peaks representing imipenem and its natural
metabolite was analyzed. The result was interpreted as positive for carbapenemase production if the specific peak for
imipenem at 300.0 m/z disappeared during the incubation time and if the peak of the natural metabolite at 254.0 m/z
increased as measured by the area under the curves leading to a ratio between the peak for imipenem and its metabolite
being ,0.5. This assay, which was applied to the large series of A. baumannii clinical isolates, showed a sensitivity of 100.0%
and a specificity of 100.0%. Our study is the first to demonstrate that this quick and simple assay can be used as a routine
tool as a point-of-care method for the identification of A. baumannii carbapenemase-producers in an effort to prevent
outbreaks and the spread of uncontrollable superbugs.
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Introduction
Carbapenems, the most common of which are imipenem and
meropenem, are among the drugs of choice for the treatment of
nosocomial infections due to Acinetobacter baumannii [1]. However,
their efficacies are increasingly becoming compromised because of
the worldwide emergence of resistant isolates [2–4]. This
resistance is principally caused by the production of carbapene-
mases, enzymes that are grouped into the following four classes
according to their molecular structure: 1) Ambler class A b-
lactamases, which are partially inhibited by clavulanic acid; 2)
Ambler class B b-lactamases, which are also referred to as metallo-
b-lactamases (MBL) because of the presence of a Zn
2+ ion within
the active site; 3) Ambler class C b-lactamases; and 4) Ambler class
D b-lactamases, which are also referred to as oxacillinases (or
OXA-type b-lactamases) and are serine-site enzymes [5,6]. For A.
baumannii, carbapenem resistance is principally mediated by the
production of oxacillinases, mainly the blaOXA-23-like, blaOXA-24-like
and blaOXA-58-like gene products [7–13]. Each of these enzymes is
able to hydrolyze the amide bond of the b-lactam ring of
carbapenems [6].
Currently, there is no standardized direct phenotypic method
for the detection of A. baumannii carbapenemases in routine
microbiological laboratories, although there are indirect methods
that are based on the ability of some compounds to inhibit
carbapenemases. For example, MBLs are susceptible in vitro to
inhibition by EDTA, but phenotypic MBL detection using the E-
test containing imipenem with or without EDTA is not reliable
because there can be false positives [14]. OXA-type carbapene-
mases are usually susceptible to NaCl inhibition, but some do not
hydrolyze oxacillin or cloxacillin [5]. In addition, NaCl-mediated
in vitro inhibition of their activity is not always observed, and
moreover, OXA-positive clinical isolates often express additional
non-OXA-type carbapenemases. PCR-based methods remain the
optimal tool for the identification of OXA-type carbapenemases,
but the main disadvantages of such technologies include cost, the
requirement for trained personal, and the inability to detect novel
carbapenemase genes [15].
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inexpensive test for the detection of carbapenemase activity. The
rapid detection of resistant strains is critical and will benefit patient
care by hastening diagnoses, optimizing therapy with antibiotics
and preventing outbreaks. Recently, it was demonstrated that the
detection of carbapenemase activity in Enterobacteriaceae and
Pseudomonas aeruginosa could be achieved through the detection of
the ertapenem and meropenem molecules and their natural
degradation products using matrix-assisted laser desorption
ionization-time of flight (MALDI-TOF) [16,17]. Herein, we
describe the development and successful application of a mass
spectrometry profile generated by matrix-assisted laser desorption
ionization-time of flight (MALDI-TOF) that utilized the imipenem
antibiotic for the detection of carbapenem resistance in a large
series of A. baumannii clinical isolates from France and Algeria.
Results
Identification of bacteria, antibiotic susceptibility testing
and molecular characterization of carbapenemase
encoding genes
All 106 isolates were identified as A. baumannii using MALDI-
TOF MS, with score values above 2.2 for all strains. Results of
antibiotic susceptibility testing showed that among the 106 A.
baumannii strains, 63 were found to be resistant to imipenem (MICs
.8 mg/L confirmed using Etest). All 63 strains were checked for
the presence of carbapenemase encoding genes and results showed
that 57 of them harbored a blaOXA-23 gene (17 were isolated in
Marseille and 40 in Algeria), 3 harbored a blaOXA-24 gene (isolated
in Algeria) and 3 a blaOXA-23+blaOXA-24 gene (isolated in Algeria)
(Table 1).
Standardization and internal calibration of the Ultraflex I
mass spectrometer with imipenem solution
Theoretical atomic masses of imipenem (C12H17N3O4S) and its
natural metabolite (C11H17N3O2S) (Figure 1A) were calculated
using ISIS Draw software and were at 299.35 g/mol and
255.35 g/mol, respectively. The three matrix described in
methods were tested with 0.45% NaCl and then combined with
imipenem. The matrix containing acetone with ethanol and TFA
provided spectra with the most useful data, i.e., without additional
background peaks at the imipenem and imipenem natural
metabolite peaks positions. Therefore, this matrix was selected
for all further tests. Firstly we established and standardize the mass
spectrum of pure imipenem in order to calibrate the mass
spectrometer to check for the presence and reproducibility of
detection of both imipenem and its natural metabolite. The
characteristic mass spectrum of pure imipenem consists of both a
main peak at 300.0+/20.2 m/z for imipenem (n=200 experi-
ments) and a weak peak at 254.0+/20.1 m/z for the natural
metabolite (n=200 experiments) (Figure 1B). In order to
standardize our assay we decide to include for each bacterial
isolate tested a ratio calculation between area under curve of
imipenem and its metabolite allowing a precise and reproducible
internal control of the experiments. Finally, we have checked for
autodegradation of imipenem to ensure that the compound was
stable during the experiments and we show that the presence of
imipenem was stable during 6 hours of incubation with a ratio
Table 1. Characterization of the 149 bacterial strains analyzed and data summary of imipenem hydrolysis assay utilizing MALDI-
TOF MS.
MALDI-TOF analysis
Strain type: No. of isolates
(Location of isolates [No.of isolates])
Range of the ratio of the area of
imipenem/metabolite based on the time
of incubation
No. of isolates detected as carbapenemase
producers (disappearance of the peak at
300 m/z or ratio between the peak for
imipenem and its metabolite being ,0.5)
based on the time of incubation
2h 4h 2h 4h
Carbapenem-resistant strains (70)
(imipenem MIC .8 mg/L)
67 70
K. pneumoniae KPC: 1 ,0.01 ,0.01 1 1
K. pneumoniae NDM-1: 2 ,0.01 ,0.01 2 2
P. aeruginosa VIM: 2 ,0.01 ,0.01 2 2
P. aeruginosa IMP: 2 ,0.01 ,0.01 2 2
A.baumannii blaOXA23-like: 57 (Marseille [17], Algeria [40]) ,0.01–1.77 ,0.01–0.23 54 57
A.baumannii blaOXA24-like: 3 (Algeria) ,0.01 0.02–0.04 3 3
A.baumannii blaOXA23-like+blaOXA24-like: 3 (Algeria) ,0.01–0.48 ,0.01–0.06 3 3
Carbapenem-susceptible strains (79)
(imipenem MIC £2 mg/L)
00
K. pneumoniae ESBL: 31 (Algeria) ND 0.64–14.84 0 0
K. pneumoniae non ESBL: 4 (Algeria) ND 1.24–5.82 0 0
Escherichia coli ATCC 25922 (1) 1.64 1.17 0 0
A. baumannii: 43 (Marseille [1], Algeria [42]) 0.61–12.86 0.97–4.96 0 0
doi:10.1371/journal.pone.0031676.t001
Acinetobacter baumannii Carbapenemase by MALDI-TOF
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always .1 (Figure S1).
Imipenem hydrolysis assay
Kinetic studies of imipenem degradation were performed for
the three carbapenem-resistant K. pneumoniae reference strains (one
blaKPC and two blaNDM-1). These strains were incubated in the
presence of imipenem at a concentration of 0.25 mg/mL for up to
four hours, and the results indicate that the three strains
completely degraded imipenem within 15 min. The peak at
300.0 m/z completely vanished whereas the peak at 254.0 m/z
increased during the experiment. Experiments performed with the
E. coli ATCC 25922 reference strain confirmed that this strain
does not contain carbapenemase activity, as both the peak at
300.0 m/z and at 254.0 m/z were still present after 4 hours of
incubation. Kinetic studies were also performed on eight A.
baumannii strains (six strains resistant to imipenem and two strains
sensitive to imipenem i.e strain SDF and strain AYE) at an
imipenem concentration of 0.25 mg/mL and an incubation time
of 2 hours. With these parameters, the peak at 300.0 m/z
disappeared for each of the carbapenem-resistant strains
(Figure 2) except one with an increase of the area under curve
for the peak at 254.0 m/z. Interestingly, although the carbape-
nem-resistant strain for which the peak at 300.0 m/z did not
completely disappear after 2 hours, the ratio of the area of the two
peaks at 2 hours was ,0.5, and the peak disappeared using
4 hours of incubation. Finally, for the two carbapenem-sensitive
strains, the peak at 300.0 m/z was consistently present during the
test both after 2 hours and 4 hours of incubation (Figure 3), and
the ratio of the area of imipenem/metabolite was .0.5,
confirming that these strains do not contain carbapenemase
activity.
The imipenem hydrolysis assay was performed blindly twice on
the 149 strains listed in Table 1 using the two criteria listed above,
i.e., the disappearance of the peak at 300.0 m/z along with an
increase of the peak at 254.0 m/z leading to a ratio of the area
between the two peaks ,0.5, to identify carbapenemase activity.
These strains included 63 carbapenem-resistant A. baumannii
strains containing either the blaOXA23-like and/or blaOXA24-like
carbapenemase-encoding genes (46 from Algeria and 17 from
Marseille, France), 43 carbapenem-sensitive A. baumannii strains
(42 from Algeria and one from Marseille, France), 35 carbapenem-
sensitive K. pneumoniae strains (31 ESBL producers with CTX-M15-
, TEM- and SHV-encoding genes and four non-ESBL producers),
and the eight control strains listed above (Table 1). Results showed
that after 2 hours of incubation time, a carbapenemase activity
was observed for all the carbapenem-resistant control strains
tested, with disappearance of the peak at 300 m/z and a ratio of
the area of imipenem/metabolite ,0.5. Concerning the 63
carbapenem-resistant A. baumannii strains disappearance of the
peak at 300 m/z was observed after 2 hours of incubation for 60
strains and was achieved for all strains after 4 hours of incubation
(see additional examples in Figure S2). Concerning the carbape-
nem-sensitive controls, no carbapenemase activity was detected
after 2 or 4 hours of incubation (presence of the peak at 300 m/z
and ratio of the area of imipenem/metabolite .0.5). Similarly, the
Figure 1. MALDI-TOF MS analysis of imipenem. (A) Imipenem and its natural degradation product. (B) Mass spectra of imipenem and its natural
degradation product as determined using the Ultraflex mass spectrometer.
doi:10.1371/journal.pone.0031676.g001
Acinetobacter baumannii Carbapenemase by MALDI-TOF
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of the peak at 300 m/z (see additional examples in Figure S2) and
a ratio of the area of imipenem/metabolite .0.5 whatever the
time of incubation tested. Thus in all experiments, disappearance
of the peak at 300 m/z was correlated with a ratio ,0.5 (Table
S1). The overall sensitivity and specificity for the detection of
Figure 2. Mass spectra of the imipenem hydrolysis assay with a carbapenem-resistant A. baumannii strain. Incubation at 37uC during
4 h; NaCl 0.45%; imipenem concentration 0.25 mg/mL. Units of the x axis represent the mass per charge in Daltons [m/z (Da)] and that of the y axes,
the relative intensity (a.u., arbitrary units).
doi:10.1371/journal.pone.0031676.g002
Figure 3. Mass spectra of the imipenem hydrolysis assay with a carbapenem-sensitive A. baumannii strain. Incubation at 37uC during
4 h; NaCl 0.45%; imipenem concentration 0.25 mg/mL Units of the x axis represent the mass per charge in Daltons [m/z (Da)] and that of the y axes,
the relative intensity (a.u., arbitrary units).
doi:10.1371/journal.pone.0031676.g003
Acinetobacter baumannii Carbapenemase by MALDI-TOF
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95.2% and 100.0%, respectively after two hours of incubation with
imipenem, and 100.0% and 100.0% respectively, after four hours
of incubation. Thus, a concentration of 0.25 mg/L of imipenem
and an incubation time of 4 hours were the optimal conditions.
Discussion
The MALDI-TOF MS technique has recently been introduced
as a fast and reliable identification method that can be used for
routine applications in diagnostic laboratories [18]. This rapid,
simple, inexpensive and high-throughput proteomic system has
been shown to be useful in bacteria and yeast identification [19].
This method has also commonly been used for proteomic research
at the molecular level [20]. In our study, the MALDI-TOF MS
system was used for the detection of carbapenemase activity in a
large collection of A. baumannii strains isolated in France and
Algeria. The strains were characterized according to their
resistance mechanisms using phenotypic tests, including antibiotic
susceptibility testing on agar plates, and also using genotypic tests,
including the search for oxacillinases- and Ambler class B b-
lactamase-encoding genes.
The direct detection of carbapenemase activity using similar
approaches involving MALDI-TOF was recently reported in two
studies of P. aeruginosa and Enterobacteriaceae [16,17], but to our
knowledge, this was the first time that the direct detection of
carbapenemase activity was developed using imipenem as the
carbapenem compound and including a large collection of A.
baumannii clinical isolates and other bacterial strains (a total of 149
bacterial strains). Indeed, in these two previous studies, either
ertapenem [16] or meropenem [16] was used to detect
carbapenemase activity for 87 bacterial isolates (including 47
carbapenem-resistant strains) and 124 bacterial isolates (including
30 carbapenem-resistant strains), respectively. However, the
MALDI-TOF assay used in the current study was different from
that used in these two previous reports. First, in this study, we used
an Ultraflex I mass spectrometer, which has greater resolution and
greater sensitivity than the Microflex mass spectrometer that was
used previously [16,17]. The Ultraflex is a more reliable
instrument because it contains 2 tubes for flight with a total of
2.76 meters versus only one tube of 0.95 meters for the Microflex
apparatus. Moreover, the Ultraflex provides improved resolution
of peaks when the positive reflectron ion mode is used between m/
z 0 and 1000 Da (Data Bruker Daltonics). Finally, the Ultraflex
has increased sensitivity when AnchorChip target plates covered
with a hydrophobic surface with a hydrophilic center are used,
which also leads to a higher concentration of the molecules to be
ionized. Second, before testing clinical isolates, we evaluated
different matrices to optimize the detection of imipenem and to
limit the noise due to the matrix itself. Our results indicated that
the HCCA matrix diluted in a mixture of acetone, ethanol and
TFA was ideal to visualize the imipenem mass spectra with the
Ultraflex instrument, as the background noise was low for this
condition. The peak of imipenem molecule can be visualized at
300.0+/20.2 m/z, as well as the natural degradation product at
254.0+/20.1 m/z. The presence of the peak of the metabolite at
254 m/z even in the absence of any bacterial colonies could be
explained by the fact that there is a spontaneous degradation of
imipenem in sodium chloride [21]. This was also observed by
Burckhardt et al with ertapenem (476 Da) and its natural
hydrolyzed and decarboxylated ertapenem metabolite (450 Da)
[16]. In order to consider this low amount of metabolite we have
standardized our assay with calculation of the ratio of area under
curves between imipenem and its metabolite to take this
phenomenon into account. These peaks were highly reproducible
and corresponded to the masses of the analytes studied, which
allowed for the confirmation of their identities. Third, the method
used in this study (Ultraflex machine+AnchorChip target+HCCA
matrix) had the benefit that only the native imipenem molecule
and its metabolite were detected without the sodium salt variants
that were found with the Microflex method [16,17]. Thus, using
our method, a carbapenem-sensitive strain could easily be
identified by the presence of the peak at 300.0 m/z after 4 hours,
and a carbapenem-resistant strain could be identified by the
disappearance of this peak after 4 hours of incubation. Interest-
ingly, we observed the same phenomenon with meropenem.
However, imipenem was preferable over meropenem for this assay
because it has been shown to be more sensitive and specific for the
phenotypic detection of carbapenem-resistant strains. In addition,
in our hands, we observed an overlapping peak between the
meropenem antibiotic at 384.1 m/z and the matrix at 380.0 m/z
(data not shown).
The use of this MALDI-TOF carbapenemase detection assay
for the evaluation of A. baumannii clinical isolates was easy and
efficient and demonstrated both high sensitivity and specificity.
Similar sensitivity and specificity results were reported regarding
the use of meropenem for carbapenemase detection in Enterobac-
teriaceae and P. aeruginosa. [17]. Among the 43 carbapenem-
susceptible and 63 carbapenem-resistant A. baumannii strains tested,
neither false-positive nor false-negative result was observed.
Interestingly, one of the three carbapenem-resistant clinical
isolates of A. baumannii for which the peak at 300.0 m/z did not
completely disappear after 2 hours but only after 4 hours of
incubation was an isolate that had acquired resistance to colistin
and that is believed to have a reduced fitness [22], likely explaining
the delayed disappearance of this peak, which persisted up to
2 hours. Regarding the control strains, neither false-positive nor
false-negative results were noted. For all of the tested carbapenem-
sensitive strains, the imipenem peak was clearly distinguishable at
300.0 m/z regardless of the incubation time tested and the ratio of
the area of imipenem/metabolite was strictly .0.5. For the
carbapenem-resistant strains, the peak at 300.0 m/z disappeared
for all strains in all cases and the ratio of the area of imipenem/
metabolite was strictly ,0.5.
Finally, this study found that the delayed degradation of
imipenem varied according to carbapenemase type and not to the
MIC or to the ability of the blaNDM-1 and blaKPC carbapenemases
from K. pneumoniae to hydrolyze imipenem faster (,30 min) than
the blaOXA-23-like- or blaOXA-24-like carbapenemases from A.
baumannii (#2.5 h). Our results corroborate those of Burckhardt
et al., who found that ertapenem was hydrolyzed in 1 h by the
blaNDM-1 and blaKPC carbapenemases and in 1.5 to 2.5 h by the
blaIMP and blaVIM carbapenemases [16]. This difference in the
time required for complete imipenem hydrolysis suggests that
either the oxacillinases from A. baumannii have weaker carbapene-
mase activity/affinity for imipenem or that A. baumannii grows
more slowly than Enterobacteriaceae species. The detection of
carbapenem resistance using the MALDI-TOF MS method has
many advantages over other techniques, such as PCR, because it
can detect low-level carbapenemase activity at a low cost even
when the causative enzyme is unknown. Therefore, this technique
is suitable both for the rapid detection of resistance in clinical
settings and for the discovery of new carbapenemases. However,
one of the disadvantages of this method is that it can detect only
enzymatic carbapenem resistance and not resistance due to efflux
mechanisms or porin alterations in A. baumannii [16]. However,
because this assay was able to detect specific peaks corresponding
to the exact mass of the specific drug, we believe that all enzymatic
Acinetobacter baumannii Carbapenemase by MALDI-TOF
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the method presented herein.
In conclusion, because the average turnaround time for this test
was estimated to be 4 h, our study clearly demonstrates that this
assay could be used in real-time for routine use in clinical
microbiology laboratories as a point-of-care strategy to identify
carbapenemase-producing A. baumannii strains, which would aid in
the prevention of outbreaks and the spread of uncontrollable
superbugs.
Materials and Methods
Bacterial strains and carbapenemase detection
The carbapenem-resistant and carbapenem-sensitive A. bau-
mannii strains used in this study originated from the collection of
the Department of Microbiology at the University Hospital of
Marseille (France) and from Tlemcen, Setif, Sidi Bel Abbes,
Oran and Tizi Ouzou (Algeria) (Table 1). Species were identified
using the Bruker Daltonics Ultraflex MALDI-TOF MS method
(Bremen, Germany), as previously described [23]. Susceptibility
results for each A. baumannii strain were determined using the
disc diffusion method. The MIC for imipenem was determined
using the E-test method and was interpreted according to the
guidelines recommended by the Comite ´ de l’Antibiogramme de
la Socie ´te ´F r a n c ¸aise de Microbiologie (CA-SFM) (www.sfm-
microbiologie.org/). For each of the A. baumannii strains, genes
encoding the Ambler class B and D carbapenemases were
identified by PCR with primers specific for the blaIMP, blaVIM,
blaNDM, blaOXA-23-like, blaOXA-24-like, blaOXA-51-like and blaOXA-58-
like genes as previously described [24]. Four carbapenem-
resistant P. aeruginosa strains (two blaVIM and two blaIMP), three
carbapenem-resistant Klebsiella pneumoniae strains (one blaKPC and
two blaNDM-1), one carbapenem-susceptible E. coli reference
strain ATCC 25922, and 35 carbapenem-sensitive K. pneumoniae
strains (31 ESBL producers and four non-ESBL producers) were
used as controls (Table 1). For kinetic studies, the carbapenem-
sensitive A. baumannii reference strains AYE and SDF [25] were
used as well as six well characterized carbapenem-resistant
strains.
MALDI-TOF MS analysis of imipenem
Commercially available imipenem that contains cilastatin
(Tienam, 500 mg, MSD, Paris, France) was diluted in 0.45%
NaCl. The MALDI-TOF analysis was performed using the spectra
of low molecular masses ranging from 0 to 1000 Da. Due to the
background peaks from the low molecular masses of the matrix,
three organic matrices were tested: 1) 10 mg/ml a-cyano-4-
hydroxycinnamic acid (HCCA); 2) 2,5-dihydroxybenzoic acid
(DHB) diluted in acetonitrile and water (1/1) and 3) 3.3 mg/ml of
a-cyano-4-hydroxycinnamic acid (HCCA) diluted in a mixture of
acetone, ethanol and TFA (1/2) (all reagents were obtained from
Sigma-Aldrich, Lyon, France).
One microliter of the matrix solution was mixed with one
microliter of the sample, which was applied onto a target (Bruker
Daltonics GmbH, Bremen, Germany; MTP AnchorChip
TM 384
T F Target) and allowed to dry at room temperature. Mass
spectra were acquired using an Ultraflex I mass spectrometer
and the flexControl 3.0 software (Bruker Daltonics GmbH)
operating in positive reflection ion mode between m/z 0 and
1000 Da. The parameters were set as follows: ion source 1:
25 kV; ion source 2: 21.5 kV; lens: 10 kV; reflector 1: 25.5 kV;
reflector 2: 14.19 kV; pulsed ion extraction: 10 ns; and detection
gain: 9.16. A total of 500 shots were acquired in 5 different
positions for one spectrum.
Standardization and internal calibration of the Ultraflex I
mass spectrometer
The imipenem concentrations that were tested for calibration of
the mass spectrometer ranged from 0.25 mg/mL to 2 mg/mL.
For internal calibration of the Ultraflex mass spectrometer, we
established the mass spectrum of pure imipenem that also contains
a natural degradation product during time as demonstrated by
Swanson et al [21]. The theoretical peaks of imipenem and its
natural degradation product were calculated using ISIS Draw
software and were used for internal calibration of the Ultraflex
apparatus in a set of 200 independent experiments. Once these
peaks were determined, they were used as internal calibration
controls for the imipenem hydrolysis assay. Finally, stability of
imipenem molecule was checked in a 6 hours incubation assay.
Imipenem hydrolysis assay
Cultures of the A. baumannii strains and the controls were
incubated overnight on blood agar plates (bioMe ´rieux, Lyon,
France) at 37uC. Then, a 10-ml loop-sized amount of bacteria was
added to 1 mL 0.45% NaCl, as previously described by
Burckhardt et al. [16], with or without imipenem at concentrations
ranging from 0.25 mg/mL to 2 mg/mL, and the cultures were
incubated for up to 4 h at 37uC. The tubes were then centrifuged
for 3 min at 12,0006 g, and 1 ml of the clear supernatant was
applied to each target spot, mixed with one microliter of matrix
solution and left to dry at room temperature. After preparing and
validating the analytical and technical aspects of the assay
(incubation time, concentration to be used, reproducibility of the
drug and metabolite peaks), all tests with clinical isolates were
conducted blindly and in duplicate. Two spots of each clinical
isolate were performed in all experiments.
Spectra analysis and interpretation of carbapenemase
activity
For one spectrum, approximately 500 shots were totaled. The
result was interpreted as positive for carbapenemase production if
the specific peak for imipenem (300.0 m/z, see results section)
disappeared completely during the incubation time and if the peak
of the natural metabolite at 254.0 m/z (see results section)
increased as measured by the area under the curves leading to a
ratio between the peak for imipenem and its metabolite becoming
,0.5.
Supporting Information
Figure S1 Mass spectra of pure imipenem showing the
stability of the drug (presence of the specific peak at
300 m/z) during a 6 hours incubation time.
(EPS)
Figure S2 Mass spectra of 24 clinical isolates of A.
baumannii obtained after 4 hours of incubation showing
the disappearance of the peak at 300 m/z for resistant
isolates (n=15) and the persistence of this peak for
susceptible isolates (n=9). Strain numbers (S.) are those
presented as * in Table S1.
(PDF)
Table S1 Area under curves (AUC) and ratio between
imipenem peak and its metabolite for the 106 Acinetobacter baumannii
clinical strains according to their location and phenotype of
resistance to imipenem. R=resistant; S=susceptible. *=strains
for which mass spectra at 300 m/z are provided in Figure S1.
(DOC)
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